Novo Nordisk A/S
$ 47.99
0.88%
04 Dec - close price
- Market Cap 211,376,325,000 USD
- Current Price $ 47.99
- High / Low $ 48.24 / 47.37
- Stock P/E 13.10
- Book Value 38.23
- EPS 3.63
- Next Earning Report 2026-02-04
- Dividend Per Share $11.65
- Dividend Yield 3.63 %
- Next Dividend Date -
- ROA 0.21 %
- ROE 0.72 %
- 52 Week High 109.50
- 52 Week Low 43.08
About
Novo Nordisk A/S (NVO) is a premier global healthcare company headquartered in Bagsvaerd, Denmark, renowned for its expertise in diabetes care, obesity treatment, and hormone replacement therapies. The company stands at the forefront of innovation, utilizing advanced biotechnology and rigorous scientific research to develop and manufacture high-quality pharmaceutical products aimed at chronic disease management. As a leader in the biopharmaceutical sector, Novo Nordisk is dedicated to enhancing patient outcomes and promoting sustainability, while upholding a strong commitment to ethical business practices and corporate responsibility.
Analyst Target Price
$53.26
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-04 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-01-31 | 2023-11-02 | 2023-08-10 | 2023-05-04 | 2023-02-01 |
| Reported EPS | 4.5 | 5.96 | 6.53 | 6.34 | 6.12 | 0.66 | 0.83 | 0.71 | 0.73 | 0.67 | 0.63 | 0.41 |
| Estimated EPS | 4.24 | 6 | 6.07 | 6.12 | 5.92 | 0.7366 | 0.77 | 0.66 | 0.69 | 0.63 | 0.61 | 0.4329 |
| Surprise | 0.26 | -0.04 | 0.46 | 0.22 | 0.2 | -0.0766 | 0.06 | 0.05 | 0.04 | 0.04 | 0.02 | -0.0229 |
| Surprise Percentage | 6.1321% | -0.6667% | 7.5783% | 3.5948% | 3.3784% | -10.3991% | 7.7922% | 7.5758% | 5.7971% | 6.3492% | 3.2787% | -5.2899% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 5.87 |
| Currency | USD |
Previous Dividend Records
| Aug 2025 | Apr 2025 | Aug 2024 | Apr 2024 | Aug 2023 | Apr 2023 | Aug 2022 | Apr 2022 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-08-26 | 2025-04-08 | 2024-08-26 | 2024-04-02 | 2023-08-29 | 2023-04-04 | 2022-08-23 | 2022-04-05 | None | None |
| Amount | $0.584816 | $1.099206 | $0.5169016 | $0.92985 | $0.8835613 | $1.1887415 | $0.5835507 | $1.0360282 | $0.5570941 | $0.9493578 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVO
2025-10-19 16:00:00
A new study in Scientific Reports by Virginia Tech researchers indicates that GLP-1 drugs like Ozempic may physically alter how the body processes alcohol, potentially changing both neurological reward and gastric emptying. This finding builds on anecdotal evidence and smaller studies suggesting GLP-1s reduce alcohol cravings, though further research with larger test groups is needed to fully understand their impact on addiction.
2025-10-19 08:00:00
Young Native Americans are taking the lead in directing $720,000 from Newman's Own Foundation and Novo Nordisk to combat food insecurity in tribal communities through the Indigenous Tomorrows Fund. Organized by Native Americans in Philanthropy, this initiative allowed 21 Indigenous leaders, aged 16-24, to establish selection criteria and choose two dozen finalists for grants. The program focuses on self-determination and intergenerational relationship-building, addressing the disproportionately high rates of food insecurity in Indigenous communities and aiming for increased funding in the future.
2025-10-19 00:25:42
Boots Online Doctor has launched a 12-month withdrawal programme for patients coming off weight-loss injections like Mounjaro and Ozempic. This program aims to prevent weight regain by offering unlimited support from clinicians, personalized online resources, and advice on lifestyle changes. It is free for those who have used Boots's weight-loss service for at least six months, addressing the lack of NHS support for privately funded users.
2025-10-18 17:09:12
Novo Nordisk's oral GLP-1 medicine, Rybelsus, has received U.S. approval to reduce the risk of major cardiovascular events, such as stroke, in adults with type 2 diabetes. This approval expands the indications for the Danish drugmaker's GLP-1 pill.
2025-10-18 16:15:00
Novo Nordisk Qatar and Ebn Sina Medical hosted the second ACT Summit in Doha on October 17-18, bringing together over 350 healthcare professionals from more than 12 countries. The summit focused on advancing cardio-metabolic treatment, particularly addressing cardiovascular kidney metabolic complications of Type 2 diabetes and obesity. The event reinforced Novo Nordisk's commitment to education and reflected Qatar's growing role in medical excellence, with participants discussing integrated care and collaborative solutions for cardio-metabolic diseases.
2025-10-18 05:00:00
Young Native Americans are taking the lead in addressing food insecurity within tribal communities, backed by a $720,000 fund from Newman's Own Foundation and Novo Nordisk. Organized by Native Americans in Philanthropy, 21 emerging Indigenous leaders aged 18-32 selected two dozen finalists to split the funding, emphasizing a unique approach to grant-making that prioritizes community involvement and Indigenous values. This initiative highlights the critical need for increased philanthropic support for Native American-led organizations, which currently receive less than 0.5% of large U.S. foundation funding.
